ACTRN12620000697987已完成2 期
A Phase II, Randomized, Double-blind, Vehicle-controlled Study to Investigate the Efficacy, Safety, and Tolerability of HXP124 in Patients with Mild to Moderate Onychomycosis.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Hexima Ltd
- 入组人数
- 117
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •1. Presence of mild to moderate clinically diagnosed DLSO, defined as involving at least 20% but not more than 60% nail plate involvement of at least one great toenail as determined by visual inspection at screening after the nail has been trimmed;
- •2. Confirmed diagnosis of onychomycosis by positive mycological microscopic examination (staining by potassium hydroxide (KOH) for dermatophyte hyphae) and positive dermatophyte culture or a mixed culture of dermatophytes/Candida from the target great toenail at screening;
- •Note: It is known that both cultures and stains may yield false negative results. If the stain
- •exhibits fungal elements or septate hyphae but the culture fails to grow a fungus, the culture may be repeated. If the culture grows but the stain does not exhibit fungal elements or septate hyphae, the stain may be repeated. If two sequential cultures or two subsequent stains are negative, the nail should not be included in the study.
- •3. The combined thickness of the distal nail plate at the associated hyperkeratotic nail bed is less than or equal to 3 mm at screening;
- •4. A clear nail distance of less than or equal to 3 mm from the proximal nail fold at screening;
- •5. Males and females aged 18-70 years (inclusive) in otherwise good health based on past
- •medical history, physical examination, vital signs, ECG, and laboratory tests at screening, as determined by the PI;
- •Note: Participants with Type 2 diabetes mellitus (T2DM) under glycemic control who
- •manage their condition only by diet/exercise will be considered for study participation, at the discretion of the PI.
- •6. Negative test for selected drugs of abuse prior to enrollment. A positive result may be
- •verified by re-testing (up to one false positive result permitted) and may be followed up at
- •the discretion of the PI;
- •7. Females must be non-pregnant and non-lactating, and either surgically sterile (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or use a highly effective contraceptive method (oral contraceptives pills (OCP’s), long acting implantable hormones, injectable hormones, a vaginal ring or an intrauterine device (IUD)) from screening until at least 30 days after the last application of study drug or be post-menopausal for less than or equal to 12 months. Post-menopausal status will be confirmed through testing of follicle stimulating hormone (FSH) levels (less than or equal to 40 IU/mL) at screening for amenorrheic female participants. Females who are abstinent from heterosexual intercourse (for the duration of the dosing period plus 1 month) will also be eligible. Female participants in same sex relationships do not need to use contraception;
- •8. Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and at Day 1 and be willing to have additional pregnancy tests as required throughout the study;
- •9. Willing and able to provide voluntary signed informed consent prior to study entry;
- •10. Willing and able to comply with all scheduled visits, laboratory tests, and other study
- •procedures.
排除标准
- •Exclusion Criteria
- •1.Presence of dermatophytoma in the target great toenail;
- •2.Lunula (matrix) involvement or exclusively lateral disease in the target great toenail;
- •3.Presence of hyperkeratotic/moccasin-type tinea pedis (athletes’ foot) at screening or baseline visits;
- •4.Presence of toenail infection other than being caused by dermatophytes and Candida;
- •5.Previous toenail surgery of the target great toenail;
- •6.Presence of more than 6 infected toenails and/or any infected fingernails;
- •7.Presence of any disease or condition other than DLSO that might cause nail abnormalities or interfere with the evaluation of the study drug;
- •8.Pregnant or lactating female at screening or plans to become pregnant or breastfeed from the time of enrolment until 30 days after the last application of study drug;
- •9.Use of any systemic antifungal therapy with known activity against dermatophytes within 12 weeks prior to the Screening visit part 1;
- •10.Non-responsiveness to prior systemic antifungal therapy for onychomycosis;
- •11.Use of any prescription or over-the-counter topical antifungal therapy for the feet within 4 weeks prior to screening part 1 (does not include topical antifungals for treatment of tinea pedis which can be used during the study);
- •12.Use of topical anti-inflammatories, corticosteroids and immunomodulators applied to the toe area within 2 weeks of screening part 2. Participants are not excluded for concomitant drugs that inhibit cytochrome P450 3A4;
- •13.Use of systemic immunomodulators and/or corticosteroids (including intramuscular injections of corticosteroids) within 4 weeks of screening part 2;
- •14.A history of immunosuppression and/or clinical signs indicative of possible immunosuppression, known human immunodeficiency virus or infection;
- •15.Use of any investigational or non-registered drug or vaccine within 30 days or 5 half-lives (whichever is longer) preceding treatment period 1 or planned use during the study period;
- •16.Unwilling to refrain from the use of nail cosmetics such as clear and/or colored nail lacquers from the screening visit until study completion;
- •17.Diagnosis of Diabetes mellitus which is not stable and controlled by diet/exercise;
- •18.Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the participant inappropriate for entry into this study;
- •19.Seropositive for HIV or Hepatitis C Virus (HCV) or Hepatitis B surface antigen (HBsAg) positive at screening;
- •20.History of severe allergy (requiring hospital care), severe reaction to any drug, or any known or suspected allergies or sensitivities to HXP124 or analogous drugs or excipients;
- •21.History of alcohol or drug abuse that in the opinion of the Investigator could affect the participants’ safety or compliance with study;
- •22.Participant who, in the judgment of the Investigator, is unwilling or unable to comply with the restrictions described in this protocol.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Study Evaluating the Safety, Efficacy and Pharmacokinetics of Single Dose EP-104IAR for 24 Weeks in Patients with Osteoarthritis of the KneeOsteoarthritis of the kneeMedDRA version: 21.1Level: LLTClassification code 10023476Term: Knee osteoarthritisSystem Organ Class: 100000004859EUCTR2021-000859-39-DKEupraxia Pharmaceuticals Inc.300
招募中
1 期
Effects of a new topical treatment, Victorhy, in patients with severe hand hyperhidrosisCTIS2023-507114-27-00Dryox Health S.L.60
已完成
2 期
A phase 2, randomized, double blind, vehicle controlled, parallel group study to explore the efficacy, pharmacodynamics and safety of topical ionic contra-viral therapy (ICVT), comprised of digoxin and furosemide in actinic keratosisActinic keratosis10014982NL-OMON48691Maruho Co., Ltd.32
进行中（未招募）
1 期
Topical ionic contra-viral therapy in actinic keratosisActinic keratosisMedDRA version: 20.0Level: PTClassification code 10000614Term: Actinic keratosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2018-000034-36-NLCutanea Life Sciences32
进行中（未招募）
1 期
A norovirus vaccine studyPrevention of gastroenteritis caused by norovirusMedDRA version: 16.1Level: PTClassification code 10068189Term: Gastroenteritis norovirusSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-001419-64-BETakeda Vaccines (Montana), Inc.420